Shares of Moderna (MRNA) rose 6.2% on Apr 9 after management announced encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in certain patients with head and neck cancer. The INT is being developed in collaboration with Merck (MRK) .This portion of the study evaluated the combination of mRNA-4157 and Merck’s blockbuster immuno-oncology drug Keytruda in patients with human papillomavirus negative (HPV-) head and neck squamous ...

Moderna (MRNA) shares ended the last trading session 6.2% higher at $111.60. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.2% loss over the past four weeks.Shares price rose after management reported encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in certain patients with head and neck cancer.This portion of the study evalua ...

Key TakeawaysModerna reported positive results of a small-sample trial of its experimental individualized cancer vaccine and Merck's Keytruda to treat those with head and neck cancers.The study found the combination boosted the immune response in patients.Moderna said research on using the treatment in a more advanced disease setting may be warranted. Moderna (MRNA) shares jumped Tuesday after the biotech firm reported positive results from a small trial involving those with head and neck cancers treated wi ...

Key TakeawaysThe S&P 500 edged up 0.1% on Tuesday, April 9, 2024, ahead of critical Consumer Price Index (CPI) data set to be released on Wednesday.Shares of Moderna soared after the firm's individualized cancer vaccine showed promise in treating patients with a certain type of head and neck cancer.Royal Caribbean shares moved lower amid a string of negative incidents for the cruise operator. Major U.S. equities made little headway in the session preceding the release of Consumer Price Index (CPI) report fo ...

Moderna Inc (NASDAQ: MRNA) popped as much as 10% on Tuesday after a Jefferies analyst made upbeat remarks on new data for its experimental vaccine for head and neck cancer.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.MRNA-4157 has potential beyond melanoma Copy link to section The biotech giant reported positive early-stage results for its MRNA-4157 in combination with Keytruda (Merck) as a treatment of head and neck cancer this week. Analysts at J ...

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.Life and the stock market are both about expectations, and rising above what is expected is often rewarded, while falling short can come with negative consequences. Investors might want to try to capture stronger returns by finding positive earnings surprises.Now that we know how important earnings and earnings surprises a ...

Moderna (MRNA) closed the latest trading day at $105.60, indicating a -0.9% change from the previous session's end. This change lagged the S&P 500's daily loss of 0.2%. On the other hand, the Dow registered a loss of 0.6%, and the technology-centric Nasdaq increased by 0.11%.The biotechnology company's shares have seen an increase of 12.1% over the last month, surpassing the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32%.Analysts and investors alike will be keeping a close eye on the perform ...

Before the COVID-19 pandemic, most investors likely hadn't heard of Moderna (MRNA -3.64%). At the end of 2019, it was a relatively small biotech company with only collaboration and grant revenue and no commercially available products.What followed was a wild ride in which Moderna burst into the public consciousness as it developed and began selling one of the COVID-19 vaccines, putting the company and its mRNA technology at the forefront of investors' minds. Nearly four years later, the company is in a curi ...

A few years ago, both Pfizer (PFE -0.11%) and Moderna (MRNA -3.64%) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer sold a COVID treatment too -- and these products generated billions of dollars in earnings for the companies.Pfizer and Moderna still sell these top products, but demand for them has declined as we head toward a post-pandemic world. That's weighed on earnings, pushed the companies to cut costs to match infrastruct ...

Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because she favors long-term investing. The idea is to buy promising companies for a good price and hold onto the shares for a number of years -- giving those companies time to bring products to market and grow earnings. And that should boost share performance over time.This week, Wood has been adding to her positions i ...